Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment.
Arijs, Ingrid; De Hertogh, Gert; Machiels, Kathleenet al.
2011 • In American Journal of Gastroenterology, 106 (4), p. 748-61
[en] OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes into the gut wall. This migration is regulated by cell adhesion molecules (CAMs), and selective antimigration therapies have been developed. This study investigated the effect of infliximab therapy on the mucosal gene expression of CAMs in IBD. METHODS: Mucosal gene expression of 69 leukocyte/endothelial CAMs and E-cadherin was investigated in 61 IBD patients before and after first infliximab infusion and in 12 normal controls, using Affymetrix gene expression microarrays. Quantitative reverse transcriptase-PCR (qRT-PCR), immunohistochemistry, and western blotting were used to confirm the microarray data. RESULTS: When compared with control colons, the colonic mucosal gene expression of most leukocyte/endothelial adhesion molecules was upregulated and E-cadherin gene expression was downregulated in active colonic IBD (IBDc) before therapy, with no significant colonic gene expression differences between ulcerative colitis and colonic Crohn's disease. Infliximab therapy restored the upregulations of leukocyte CAMs in IBDc responders to infliximab that paralleled the disappearance of the inflammatory cells from the colonic lamina propria. Also, the colonic gene expression of endothelial CAMs and of most chemokines/chemokine receptors returned to normal after therapy in IBDc responders, and only CCL20 and CXCL1-2 expression remained increased after therapy in IBDc responders vs. control colons. When compared with control ileums, the ileal gene expression of MADCAM1, THY1, PECAM1, CCL28, CXCL1, -2, -5, -6, and -11, and IL8 was increased and CD58 expression was decreased in active ileal Crohn's disease (CDi) before therapy, and none of the genes remained dysregulated after therapy in CDi responders vs. control ileums. This microarray study identified a number of interesting targets for antiadhesion therapy including PECAM1, IL8, and CCL20, besides the currently studied alpha4beta7 integrin-MADCAM1 axis. CONCLUSIONS: Our data demonstrate that many leukocyte/endothelial CAMs and chemokines/chemokine receptors are upregulated in inflamed IBD mucosa. Controlling the inflammation with infliximab restores most of these dysregulations in IBD. These results show that at least part of the mechanism of anti-tumor necrosis factor-alpha therapy goes through downregulation of certain adhesion molecules.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Arijs, Ingrid
De Hertogh, Gert
Machiels, Kathleen
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Lemaire, Katleen
Schraenen, Anica
Van Lommel, Leentje
Quintens, Roel
Van Assche, Gert
Vermeire, Severine
Schuit, Frans
Rutgeerts, Paul
Language :
English
Title :
Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment.
Publication date :
2011
Journal title :
American Journal of Gastroenterology
ISSN :
0002-9270
eISSN :
1572-0241
Publisher :
Acta Medica Belgica, New York, United States - New York
Teksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Infamm Bowel Dis 2008;14:1298-312.
Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for Infamma-torybowel diseases. Gastroenterology 2009;136:1182-97.
Geboes K, Riddell R, Ost A et al A reproducible grading scale for histological assessment of Infammation in ulcerative colitis. Gut 2000;47:404-9.
D'Haens GR Geboes K, Peeters M et al Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7. (Pubitemid 28093532)
Rutgeerts P, Sandborn WJ, Feagan BG et al Inf iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
Arijs I, Li K, Toedter G et al Mucosal gene signatures to predict response to inf iximab in patients with ulcerative colitis. Gut 2009; 58: 1612-9.
Gentleman RC, Carey VJ, Bates DM et al Bioconductor: open sof ware development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
Irizarry RA, Hobbs B, Collin F et al Exploration, normalization, and sum-maries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
Smyth GK. Linear models and empirical Bayes methods for assessing Differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article 3.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995; 85: 289-300.
Pfaf MW. A newmathematical model for relative quantif cation in real-time RT-PCR Nucleic Acids Res 2001;29:e45.
Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of Infammatory bowel disease. Infamm Bowel Dis 2008;14: 1715-35.
Sans M, Salas A, Soriano A et al. Differential role of selectins in experimen-tal colitis. Gastroenterology 2001;120:1162-72. (Pubitemid 32246670)
Yacyshyn B, Chey WY, Wedel MK et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercel-lular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007; 5: 215-20. (Pubitemid 46216935)
Feagan BG, Greenberg GR, Wild G et al Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507. (Pubitemid 41007865)
FeaganBG, Greenberg GR,Wild Get al. Treatment ofactive Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
Rijcken E, Mennigen RB, Schaefer SD et al. PECAM-1 (CD 31) mediates transendothelial leukocyte migration in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G446-52. (Pubitemid 47263189)
Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57-110. (Pubitemid 32566018)
Puleston J, Cooper M, Murch S et al A distinct subset of chemokines domi-nates the mucosal chemokine response in Infammatory bowel disease. Aliment Pharmacol Ter 2005;21:109-20. (Pubitemid 40222964)
Kaser A, Ludwiczek O, Holzmann S et al Increased expression ofCCL20 in human Infammatory bowel disease. J Clin Immunol 2004; 24: 74-85. (Pubitemid 38375798)
Banks C, Bateman A, Payne R et al Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003;199:28-35. (Pubitemid 36054726)
Kwon JH, Keates S, Bassani L et al. Colonic epithelial cells are a major site of macrophage Infammatory protein 3alpha (MIP-3alpha) production in normal colon and Infammatory bowel disease. Gut 2002; 51: 818-26. (Pubitemid 35408603)
Nishimura M, Kuboi Y Muramoto K et al Chemokines as novel therapeutic targets for Infammatory bowel disease. Ann NY Acad Sci 2009;1173:350-6.
Nob le CL, Abbas AR, Cornelius J et al Regional variation in gene expres-sion in the healthy colon is dysregulated in ulcerative colitis. Gut 2008;57:1398-405.
Papadakis KA, Prehn J, Moreno STet al CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001;121:246-54. (Pubitemid 32729371)
Izutani R Loh EY, Reinecker H-C et al Increased expression of interleukin-8 mRNA in ulcerative colitis and Crohn's disease mucosa and epithelial cells. Infamm Bowel Dis 2006;1:37-47.
Daig R Rogler G, Aschenbrenner E et al Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not inter-leukin-1 or interleukin-6. Gut 2000; 46: 350-8. (Pubitemid 30313386)
